Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Xanthine Bronchodilator/Discontinued

ELIXICON

ELIXICON

Clinical safety rating

caution

Comprehensive clinical and safety monograph for ELIXICON (ELIXICON).


Mechanism of Action

Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.

What the body does with it

MetabolismPrimarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
ExcretionRenal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Half-lifeTerminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Protein bindingApproximately 40% bound, primarily to albumin.
Volume of DistributionVd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
BioavailabilityOral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
Onset of ActionOral immediate-release: 15-30 minutes; IV: rapid (within minutes); Subcutaneous: not appropriate route.
Duration of ActionImmediate-release: 4-6 hours; Extended-release: 8-12 hours or longer. Clinical note: monitor serum concentrations for sustained effect.
Molecular Weight180.16

Classification & Brands

Dosing & administration

400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.

Dosage formSUSPENSION
Renal impairmentGFR > 50 mL/min: no adjustment; GFR 10-50 mL/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 mL/min: reduce dose by 50% and monitor levels.
Liver impairmentChild-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Pediatric useInitial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Geriatric useStart at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.

Use during pregnancy

1st trimesterThere is no evidence of teratogenicity in humans; however, use only if clearly needed. Theophylline crosses the placenta and may cause fetal tachycardia. Monitor maternal serum levels closely.
2nd trimesterUse with caution; may cause fetal tachycardia and irritability. Adjust dose based on maternal serum levels to avoid toxicity. No known malformative risk.
3rd trimesterUse near term may cause neonatal irritability, jitteriness, tachycardia, and vomiting. Theophylline half-life is prolonged in neonates. Consider tapering before delivery if possible.

Clinical note

Comprehensive clinical and safety monograph for ELIXICON (ELIXICON).

Placental transferTheophylline crosses the placenta readily, achieving fetal serum levels similar to maternal levels. There is no evidence of placental biotransformation.
BreastfeedingTheophylline is excreted into breast milk in small amounts (approximately 1% of maternal dose). Peak milk levels occur 1-2 hours after a dose. In full-term infants, adverse effects are rare, but premature infants may accumulate the drug. Monitor infant for irritability or poor feeding. If maternal serum levels are kept within therapeutic range (5-15 mcg/mL), breastfeeding is generally considered safe.
Lactation RatingL3 (Moderately Safe)
Teratogenic RiskInsufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
Fetal MonitoringMonitor maternal serum drug levels, liver function, renal function, and fetal growth via ultrasound.
Fertility EffectsNo known effects on fertility in animal studies; limited human data.

Warnings & precautions

■ FDA Black Box Warning

Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to theophylline or any component of the formulationCardiac arrhythmias (especially tachyarrhythmias) that require immediate treatmentSeizure disorders (unless adequately controlled with anticonvulsants and theophylline is essential)Peptic ulcer disease (active)

Clinical Precautions

PrecautionsRisk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Food/DietaryAvoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.

Clinical Tips & Counseling

Clinical PearlsELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/mL. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Patient AdviceTake exactly as prescribed and do not change dose without consulting your doctor. · Avoid smoking and second-hand smoke as it affects how the medication works. · Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects. · Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures. · Do not take this medication with other cold or asthma remedies without medical advice.

ELIXICON Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

ACCURBRONAMINOPHYLLINAMINOPHYLLINEAMINOPHYLLINE DYE FREEELIXOMIN

External sources

DailyMed (NIH) PubMed OpenFDA